These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24019330)

  • 41. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Pilling AB; Hwang C
    Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
    Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer.
    Rhea LP; Gupta B; Aragon-Ching JB
    Asian J Androl; 2019; 21(2):107-108. PubMed ID: 30460933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
    Zhao J; Zhao Y; Wang L; Zhang J; Karnes RJ; Kohli M; Wang G; Huang H
    Oncotarget; 2016 Jun; 7(25):38551-38565. PubMed ID: 27221037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metastasis: Resistance fighters.
    Savage N
    Nature; 2015 Dec; 528(7582):S128-9. PubMed ID: 26672785
    [No Abstract]   [Full Text] [Related]  

  • 54. Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
    Ge R; Xu X; Xu P; Li L; Li Z; Bian J
    Curr Cancer Drug Targets; 2018; 18(7):652-667. PubMed ID: 29110617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
    Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
    Arora VK; Schenkein E; Murali R; Subudhi SK; Wongvipat J; Balbas MD; Shah N; Cai L; Efstathiou E; Logothetis C; Zheng D; Sawyers CL
    Cell; 2013 Dec; 155(6):1309-22. PubMed ID: 24315100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.